Trade Cumberland - CPIX CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0466 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.024318% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.002096% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 1.1767 |
| Open | 1.0867 |
| 1-Year Change | -35.92% |
| Day's Range | 1.0867 - 1.1967 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Dec 5, 2024 | 1.1567 | 0.0300 | 2.66% | 1.1267 | 1.2067 | 1.0867 |
| Dec 4, 2024 | 1.1767 | -0.0300 | -2.49% | 1.2067 | 1.2367 | 1.1567 |
| Dec 3, 2024 | 1.2067 | -0.0700 | -5.48% | 1.2767 | 1.2867 | 1.1867 |
| Dec 2, 2024 | 1.2967 | -0.0200 | -1.52% | 1.3167 | 1.3567 | 1.2767 |
| Nov 29, 2024 | 1.3267 | -0.0100 | -0.75% | 1.3367 | 1.4167 | 1.2467 |
| Nov 27, 2024 | 1.3267 | 0.2100 | 18.81% | 1.1167 | 1.5667 | 1.0567 |
| Nov 26, 2024 | 1.0967 | 0.0400 | 3.79% | 1.0567 | 1.1067 | 1.0567 |
| Nov 25, 2024 | 1.0567 | 0.0300 | 2.92% | 1.0267 | 1.0967 | 1.0167 |
| Nov 22, 2024 | 1.0467 | 0.0000 | 0.00% | 1.0467 | 1.1467 | 1.0467 |
| Nov 21, 2024 | 1.0567 | 0.0000 | 0.00% | 1.0567 | 1.0767 | 1.0467 |
| Nov 20, 2024 | 1.0767 | 0.0000 | 0.00% | 1.0767 | 1.1267 | 1.0767 |
| Nov 19, 2024 | 1.1067 | 0.0000 | 0.00% | 1.1067 | 1.1367 | 1.0867 |
| Nov 18, 2024 | 1.1167 | 0.0100 | 0.90% | 1.1067 | 1.1767 | 1.0567 |
| Nov 15, 2024 | 1.0967 | -0.0500 | -4.36% | 1.1467 | 1.1867 | 1.0567 |
| Nov 14, 2024 | 1.1667 | 0.0200 | 1.74% | 1.1467 | 1.1967 | 1.1467 |
| Nov 13, 2024 | 1.1767 | 0.0300 | 2.62% | 1.1467 | 1.1967 | 1.1467 |
| Nov 12, 2024 | 1.1967 | 0.0200 | 1.70% | 1.1767 | 1.1967 | 1.1767 |
| Nov 11, 2024 | 1.1867 | 0.0300 | 2.59% | 1.1567 | 1.2067 | 1.1567 |
| Nov 8, 2024 | 1.1867 | 0.0300 | 2.59% | 1.1567 | 1.1867 | 1.1067 |
| Nov 7, 2024 | 1.1967 | 0.0000 | 0.00% | 1.1967 | 1.2367 | 1.0767 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Cumberland Company profile
About Cumberland Pharmaceuticals, Inc.
Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription products. The Company's product portfolio includes Acetadote (acetylcysteine) Injection, for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) Injection, for the treatment of pain and fever; Kristalose (lactulose) for Oral Solution, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox Pak, (omeprazole, clarithromycin, amoxicillin) for the treatment of Helicobacter pylori (H. pylori) infection and related duodenal ulcer disease; Vaprisol (conivaptan) Injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ (telavancin) Injection, for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and RediTrex.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Cumberland Pharmaceuticals, Inc. revenues decreased 4% to $36M. Net loss before extraordinary items decreased 16% to $5.5M. Revenues reflect Acetadote segment decrease of 55% to $851K, RediTrex segment decrease of 94% to $55K. Lower net loss reflects Interest expense decrease of 63% to $98K (expense), Research and Development decrease of 2% to $5.7M (expense).
Equity composition
Common stock no par, 03/11, 100M auth., 20,432,034 issd. Insider owns approx. 37.85% .IPO:8/11/2009, 5M shares @ $17 per share by UBS Securities LLC, Jefferies & Company, Inc., Wells Fargo Securities, LLC & MorganJoseph & Co. Inc. 6/07,Stock Split 2:1.
| Industry: | Generic Pharmaceuticals |
2525 W End Ave Ste 950
NASHVILLE
TENNESSEE 37203-1608
US
News
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
09:13, 6 December 2024
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
12:47, 5 December 2024
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
09:32, 4 December 2024
Silver price forecast 2025 and beyond: Third party price target
Rising interest rates and a strong dollar pushed silver to a two-year last September, but what lies ahead?
16:00, 3 December 2024
Shiba Inu coin price prediction 2030: could Shiba Inu coin reach $1? Third party price target
Can Shiba Inu reinvent itself to become a worthy long-term investment?
16:41, 28 November 2024
Trump trades charge as Bitcoin hits $US80,000
Bitcoin hits $80,000 amid expectations of fiscal stimulus, lower regulatory risks, and resilient US economy.
10:48, 13 November 2024
Australian jobs data expected to point to solid labour market conditions
Australian labour market and wage data to reveal job growth resilience, shaping RBA rate cut expectations and impacting AUD amidst global economic shifts.
10:16, 13 November 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com